Healthcare -
Biotechnology - NASDAQ - US
$ 13.71
-5.46 %
$ 557 M
Market Cap
-2.75
P/E
CASH FLOW STATEMENT
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Keros Therapeutics, Inc.
| Net Income | -187 M |
| Depreciation & Amortization | 1.23 M |
| Capital Expenditures | -1.93 M |
| Stock-Based Compensation | 34.9 M |
| Change in Working Capital | -11.4 M |
| Others | -6.77 M |
| Free Cash Flow | -163 M |
Cash Flow
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||||
| Net Income | (187.4) | (153.0) | (104.7) | (58.7) | (45.4) | (12.3) | (1.3) |
| Depreciation & Amortization | 1.2 | 0.8 | 0.7 | 0.4 | 0.3 | 0.2 | 0.2 |
| Deferred Income Tax | 0 | 0 | 0 | 46 K | 0 | 0 | 0 |
| Stock Based Compensation | 34.9 | 28.8 | 18.7 | 11.7 | 4.1 | 59 K | 81 K |
| Other Operating Activities | 1.8 | 1.6 | 1.0 | 0.5 | 1.8 | 2.8 | 0.2 |
| Change in Working Capital | (11.4) | (2.6) | 14.3 | (16.1) | 2.3 | (6.7) | 7.9 |
| Cash From Operations | (160.9) | (124.5) | (70.1) | (62.1) | (36.9) | (16.0) | 7.0 |
| INVESTING CASH FLOW | |||||||
| Capital Expenditures | (1.9) | (2.5) | (1.2) | (1.0) | (0.3) | (0.3) | (0.2) |
| Other Items | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash From Investing Activities | (1.9) | (2.5) | (1.2) | (1.0) | (0.3) | (0.3) | (0.2) |
| FINANCING CASH FLOW | |||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 11.7 | 3.1 | 0.7 | 0.4 | 52.8 | 14 K | 11.5 |
| Cash From Financing Activities | 391.8 | 179.0 | 120.3 | 28.6 | 296.0 | 14 K | 11.5 |
| CHANGE IN CASH | |||||||
| Net Change In Cash | 229.0 | 52.0 | 49.0 | (34.6) | 258.9 | (16.3) | 18.3 |
| FREE CASH FLOW | |||||||
| Free Cash Flow | (162.8) | (127.0) | (71.3) | (63.2) | (37.2) | (16.3) | 6.8 |